Grants>Cancer Control

Call for Applications: Alex’s Lemonade Stand Foundation Bridge & Springboard Grants

Bridge Grant

Alex’s Lemonade Stand Foundation introduces a new funding opportunity for researchers whose projects are in jeopardy due to the decreased funding available from the National Institutes of Health (NIH). ALSF’s Bridge Grants are intended to keep scientist’s projects on track while they reapply for NIH funding to ensure novel childhood cancer research projects are not compromised. ALSF’s Bridge Grant awards will provide $100,000 for 12 months to be used for supplies, personnel or the Principal Investigator’s salary.

Eligibility Requirements:

Project must have been previously funded by an NIH R01, R03, R21 or P01 Award. (R01 Supplements are not eligible for Bridge Grants.)

Researchers must have applied to the NIH for an R01 or P01 renewal for an ongoing project or to continue the project via new R01 or P01 within the last 6 months.

The application must have been scored ≤25th percentile, but outside of the agency’s fundable range.

Applicants must be reapplying for an R01 or P01 Award from the NIH within the next two NIH Grant cycles.

Projects must be aligned with ALSF’s mission, thus focused on better diagnosing or curing childhood cancers.

Funds may be used for supplies, personnel or PI’s salary and may not exceed $100,000. ALSF does not pay indirect costs. 
  
Application Process:

To expedite the application progress, ALSF’s Scientific Advisory Board will review the previously reviewed NIH application along with any changes that have been made in response to feedback from NIH reviews.

A cover letter, summary statement, response to NIH critique and budget will be required by all applicants.

All applications must be submitted via ALSF’s online application.
    
Springboard Grant

ALSF’s offers the Springboard Grant in response to cut-backs in National Institutes of Health (NIH) funding of new R01 and P01 applications. The Springboard Grant is designed to jump-start new projects with high impact potential for childhood cancer research while other funding is sought. Awards will provide $100,000 for 12 months to be used for supplies, personnel or the Principal Investigator’s salary.

Eligibility Requirements:

Researchers must have applied to the NIH for an R01 or P01 award within the last 6 months. (R01 Supplements are not eligible for Springboard Grants)

Applications must have scored ≤20%, but outside of the agency’s fundable range.

Applicants must be reapplying for an R01 or P01 award from the NIH within the next two NIH Grant cycles.

Projects must be aligned with ALSF’s mission thus focused on better diagnosing or curing childhood cancers.

Funds may be used for supplies, personnel or PI’s salary and may not exceed $100,000. ALSF does not pay indirect costs. 

Application Process:

To expedite the application progress, ALSF’s Scientific Advisory Board will review the previously reviewed NIH application along with any changes that have been made in response to feedback from NIH reviews.

A cover letter, summary statement, response to NIH critique and budget will be required by all applicants.
All applications must be submitted via ALSF’s online application.

Alex's Lemonade Stand Foundation for Childhood Cancer  333 E. Lancaster Ave., #414 Wynnewood, PA 19096

Ph: 610.649.3034

Fax: 610.649.3038

Request for Proposals: International Innovation Grant

The International Innovation Grant provides research funding in support of novel and innovative projects that can have a significant impact on cancer control in low- and middle-income countries.

The International Innovation Grant is a one-year research grant of up to $20,000 that is awarded and paid directly to a nonprofit organization or governmental agency in a low-income or middle-income country. The grant may be used by the organization only for the approved, budgeted costs of the research project. Each grant will have a Principal Investigator who is an ASCO member, is affiliated with the Grantee Organization, and is a resident of the low-income or middle-income country.

International Innovation Grants are hypothesis-driven research grants that fund a specific research project that may result in the discovery of new knowledge about how to advance cancer control in a low- or middle-income setting.  It is anticipated that novel approaches and clinical designs proposed for this grant may differ from what would be considered standard practice within high-income settings.  Grantee Organizations and Principal Investigators will be expected to share and disseminate the knowledge gained during their research project.

The online system will open for Letter of Intent submission on July 1, 2013. All Letters of Intent must be submitted by August 1, 2013.

Questions? Read our Frequently Asked Questions document:

http://www.conquercancerfoundation.org/sites/conquercancerfoundation.org/files/international_innovation_grant_faq_5-1-2013.pdf

If that doesn’t answer your question, email grants@conquercancerfoundation.org.

2014 International Innovation Grant Timeline:

May 1, 2013 RFP is Released for 2014 International Innovation Grant

July 1, 2013 Online Application System Opens for Submitting Letters of Intent

August 1, 2013 Letters of Intent Due

October 3, 2013 Invited Full Applications Due

December 2013 Grant Recipients Announced

January 1 - December 30, 2014 Grant Project Period

Request for Application: Cutaneous Lymphoma Foundation’s CLARIONS Research Awards Program

The signature funding initiative of the Research Awards Program (RAP), is the CLARIONS Grant Program, which stands for Curing Cutaneous Lymphoma by Advancing Research, Innovation and Offering New Solutions.  This research grant program supports investigators interested in conducting innovative cutaneous lymphoma research.   These grants will help uncover causes and improve the treatment and quality of life for patients. Discovering new avenues for better therapies and, one day, a cure for cutaneous lymphoma are key goals of this program.

Research Funding Priorities

Eligibility and Requirements

Investigators at all levels, from clinical and post-doctoral fellows to established investigators, are eligible to receive
awards. Medical students and graduate students are not eligible. Non-U.S. investigators are eligible and the research funded by the RAP can be conducted at non-U.S. institutions. Investigators must be members of an established and recognized academic institution. All research projects involving human subjects must receive IRB approval.

Award Amounts

Each year the CLF will provide two $25,000 awards, renewable for 1 year contingent upon approval by the CLF
Board of Directors based upon the CLF Scientific Review Board’s review and recommendation.

A small indirect cost amount between $1,000-$2,000 is allowable.

The CLF’s RAP seeks to fund innovative research in all areas of cutaneous lymphomas with particular interest in:

-- Etiology and risk factors of cutaneous lymphomas.

-- Measures of disease impact on individuals and populations affected by cutaneous lymphomas.

-- Translating discoveries into diagnostic and therapeutic advances in cutaneous lymphomas.

-- Optimizing therapies for cutaneous lymphomas.

-- Improving quality of life for individuals with cutaneous lymphomas

2013 Calendar of Award Events

January 31 -  Public announcement of Request for Application (RFA)

July 31 -  Application deadline

August - October - Scientific Review Board review

November - Recipients notified of award

December - Grant awards announced at ASH meeting

January, 2014 - Disbursement of Award and beginning of new award cycle

Cutaneous Lymphoma Foundation
PO Box 374
Birmingham, MI 48012-0374

Telephone: 248-644-9014

Fax: 248-644-9014

Call for Cancer Projects: Repurposing of Drugs - Breakthrough in Cancer Treatment

Funding Cancer Projects

Reliable Cancer Therapies (RCT) announces € 300 000 for projects repurposing existing drugs for cancer treatment.  The drugs must have been developed and approved for other indication(s). Relevant clinical trial endpoints (cancer survival & tumor response) should be the primary research assessments.

RCT also promotes collaborative research projects between researchers at different universities and/or organisations.

About the Call for Applications

• Medical Degree required for Principal Investigator (PI) or co-PI

• 1 application per PI

• Resubmission is allowed (please indicate the reason for previous decline)

• Set up of proposal:

◦ Application form: maximum 2 pages

◦ in appendix 1: biography & references of the PI and co-PI

◦ in appendix 2: overview of the budget (including salaries, supplies, equipment, patient care costs, and other expenses).

• If your cancer project is selected in the first round, detailled information will be requested for consideration of the final award selections.

• Approved proposals will be supported with a maximum of  € 300 000 for 3 years.

Reliable Cancer Therapies (RCT) is a non-profit organization based in Switzerland that provides research-based information on cancer therapies and selectively funds the development of promising therapies.

RCT investigates information on cancer therapies for evidence to then inform the public about evidence-based cancer treatment choices. We help cancer patients and caregivers to structure and absorb the complex nature of cancer information for their decision-making on registered complementary or alternative therapies.

RCT is continuously looking for cancer therapies that have never been thoroughly examined and consider financing cancer treatments that can be deemed promising based on measurable results.

Application Deadline

Application deadline is June 28, 2013 at 8am GMT. Incomplete or late applications will not be considered.

Please submit applications to Ann-Christine Moenaert (info@reliablecancertherapies.com)

RCT will review the applications internally with the support from our appropriate external experts by August 14, 2013. If the project is selected in the first round, more detailled information will be requested by September 13, 2013.  Final decisions will be made on October 4, 2013.

Contacts at RCT

Please direct any technical questions to Ann-Christine Moenaert (info@reliablecancertherapies.com)

Please contact Gauthier Bouche, MD (info@reliablecancertherapies.com) for any clinical or scientific questions.

Call for Applications: Meso Foundation Research Grants

The Meso Foundation (formerly known as MARF) is the non-profit dedicated to ending the suffering caused by mesothelioma. We are the international collaboration of patients and families, physicians, advocates, and researchers dedicated to eradicating the life-ending and vicious effects of mesothelioma. We believe in a cure for meso. Given the human toll of suffering the disease causes, the compassion and energy of the meso community, the moral, legal and economic aspects of asbestos, and the benefits of meso research to cancer research generally, we believe that the resources to accomplish this cure are available and must be mobilized. We seek to marshal and utilize these resources responsibly, as effectively as possible, with financial transparency and by adhering to health policy guidelines that foster ethical clinical and administrative practices, and ethical decision making to:

·  Offer hope and support to patients and families by educating them on the disease, helping them to obtain the most up-to-date information on treatment options and to connect with meso treatment specialists, and providing them assistance, emotional support and community with others;

·  Raise awareness of meso, and advocate that the public and private sectors partner in the effort to cure it by directing the resources needed to stop this global tragedy; and

·  Fund the highest quality and most promising meso research projects from around the world through rigorous peer-review. To date we have funded 86 projects, from six different countries, totaling over 8.2 million dollars.

The Meso Foundation offers research grants for two years up to $50,000 per year. Eligible projects may relate to benchwork, translational or clinical research that is not presently funded or pending review and may be conducted through any not-for-profit academic, medical or research institution. The Foundation will review and monitor the project's progress and results, requiring semi-annual disposition of funds reports, a ten month progress report, a presentation at the Foundation’s Symposium and a full progress report at the close of the project. The Foundation seeks exceptional projects for which the Foundation's funding is demonstrated to be essential and not duplicative. Please be advised that the Foundation does not pay institutional indirect costs.

Funded researchers will also be entitled to facilitated access to the National Mesothelioma Virtual Bank (NMVB),www.mesotissue.org.They will receive expedited review of requests to use the NMVB, and they will have direct, no-cost access to materials in the bank, as well as enhanced collections from the main sites of materials.

Encouraged projects include, but are not limited to, investigations of:

1. Strategies for early detection of new or progressive disease;

2. Definition of targetable differences between normal and transformed mesothelium and development of novel strategies for treatment;

3. Therapeutic intervention, including but not limited to;

a. Immune Response Targeted Therapy

b. Novel chemotherapeutic compounds

c. Novel radiation or surgical techniques

4. Determination of clinical/molecular determinants for prognosis

Applications will be considered for funding by the Meso Foundation’s Science Advisory Board comprised of doctors and researchers who work around the world within the mesothelioma field. These members will review and score the research proposals based on the following criteria. The applications will be ranked numerically and the highest scoring projects will be recommended to the Foundation’s Board of Directors for funding. Based on the funding available, awards will be granted.

Applications will be evaluated on the following criteria:

Significance - Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

Investigator(s)- Are the PD/PIs, collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?

Innovation - Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?

Approach - Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? If the project involves clinical research, are the plans for 1) protection of human subjects from research risks, and 2) inclusion of minorities and members of both sexes/genders, justified in terms of the scientific goals and research strategy proposed?

Environment - Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

Applications should be submittedthrough proposalCENTRAL.You will find the Mesothelioma Applied Research Foundation listed with the instructions and the application required. Applications are limited to 10 pages (not including biographies) and are due no later than August 2, 2013. Final award decisions will be made in December 2013 and all applicants will be notified of the outcome.

Travel Grants for the 4th International Thymic Malignancy Interest Group Annual Meeting (ITMIG 2013)

September 6 - 7, 2013 Bethesda, Maryland

This important Conference will highlight the latest scientific and clinical developments related to the management of thymic malignancies and will bring together established scientists and clinicians from all over the world who have interest in the field of thymic cancers research.

The Conference is pleased to offer travel grants to trainees, residents and fellows.

Eligible Candidates

Trainee, resident or fellow - proof of status required

Submitting and presenting author for an abstract accepted at ITMIG 2013

Benefits

Complimentary full Conference registration

Cash award to help offset travel expenses

Supporting Application Materials

Curriculum Vitae
Recommendation/Supporting Letter from supervisor
Proof of status (trainee, resident, fellow)

How to Apply?

Send application email including supporting materials to itmig2013@icsevents.com by June 14, 2013

Submit abstract via online abstract submission form by June 14, 2013

Terms and Conditions

The organizers reserve the right to

Cancel the scholarship if a selected award winner is not attending in person

Amend the terms and conditions of the scholarship program without notice

Deadlines and Timelines

Application Deadline: June 14, 2013

Notifications: expected to be available end of July 2013

Contact

For any questions or inquries regarding travel grants, please contact the Conference Secretariat at itmig2013@icsevents.com.

Request for Proposal: Desmoid Tumor Research Foundation

Submission deadline for Applications: June 30, 2013.

The Desmoid Tumor Research Foundation, Inc. (“DTRF”) seeks to advance the science related to desmoid tumors by:

• Funding research related to the diagnosis and treatment of desmoid tumors;

• Facilitating and enhancing the dialogue among members of the medical and scientific communities about research related to desmoid tumors;

• Providing informational support for desmoid tumor patients and their families and friends, and heightening awareness of desmoid tumor diagnosis and treatment.

The purpose of this Request for Proposal is to fund research that will advance the current scientific knowledge about desmoid tumors, resulting in the development of new treatment options and bringing us closer to our ultimate goal -- a cure.  Information about DTRF can be found at www.dtrf.org.

Approach

The Desmoid Tumor Research Foundation is the only foundation in the country dedicated to facilitating and funding research for a cure for desmoid tumors.  We fund research that uses cutting-edge science and creative clinical applications, in addition to novel approaches addressing potential leads based on prior research.  Researchers must be willing to collaborate with other scientists and institutions with similar interests.  Research proposals with additional sources of funding support are particularly desirable.

Grant Amounts and Restrictions

• Grants are awarded in amounts of up to $65,000 per year.

• Funds may only be used for personnel, supplies, equipment, and/or services.

• Use of funds for institutional overhead costs is strictly prohibited.

• Use of funds for indirect costs is strictly prohibited.

• Use of funds for project costs that are funded by other sources is strictly prohibited.

• Funding duration is a minimum of 1 year. 

Eligibility for grants:  MD, PhD, or equivalent degree, and sponsorship by an Exempt Organization as defined by Section 501(c)(3) of the Internal Revenue Code (the “Sponsoring Institution”).

Call for Proposals: 2013 Yamagiwa-Yoshida Memorial International Cancer Study Grants

The Fellowships team of UICC is pleased to announce the call for proposals for the 2013 Yamagiwa-Yoshida Memorial International Cancer Study Grants. Please note that the application closing date is set to 1st July 2013.

Please find below some key information regarding the fellowship:

WHAT

• 3 months International Fellowship

• Award value of USD 10,000

AIMS

• to initiate, set-up or pursue bilateral cancer research projects with collaborating investigators abroad

• to receive training in advanced experimental research methods and techniques

• to exploit complementary skills and material

WHO

Individuals with:

• scientific or medical qualifications and a minimum of two years postdoctoral experience

• actively engaged in cancer research

• have recent publications in the international peer-reviewed literature

WHY

• 93% of the former grantees consider YY a unique opportunity to carry out international research

• 87% of the former grantees feel their fellowship significantly increased their knowledge and research skills, thus preparing them to better compete internationally

• 73% of grantees have published with their Host mentors as result of their Fellowship whilst 77% of them are still collaborating with their Hosts

• YY experience helped define the research direction of about 80% of the former grantees

• 69% of the former grantees were able to build their own research programme as result of their fellowship

Findings from a UICC survey conducted in 2012, conducted on 139 former grantees and spanning years 1998-2010.

Application closing date: 1st July 2013

UICC Yamagiwa-Yoshida Memorial International Cancer Study Grants (YY) are funded by the Japan National Committee for UICC and Kyowa Hakko Kogyo Co. Ltd., Japan

Should you have any questions, please do not hesitate to contact us at fellows@uicc.org.

Society for Immunotherapy of Cancer Young Investigator Awards Program

SITC's Young Investigator Awards support the growth and achievement of young investigators and up-and-coming researchers in the field of cancer immunotherapy. All awards are supported by the Forward Fund.

Young Investigator Awards

This year, SITC will once again offer 10 Young Investigator Awards in conjunction with the SITC 28th Annual Meeting. Award recipients are chosen based on excellence in quality of research and presentation, the strength of the results and methods, and whether the reported research significantly advances the field. All award recipients will be recognized at the Awards Ceremony at the SITC 28th Annual Meeting.

How to Apply

To be considered for an award, an abstract must be submitted online by July 17, 2013. During the online submission process, you must select the “Apply” button in the “Awards” section to be considered for an award. Award eligibility, abstract guidelines, and instructions for submitting abstracts will be posted on the Abstracts page once finalized.

Award Eligibility

To qualify for a Young Investigator Award, the primary/presenting author must submit an abstract by the deadline and meet the following membership and young investigator criteria:

• Must be a member of SITC current in dues prior to abstract submission.

• Primary/Presenting author must be a Student, Post doctoral research fellow, Clinical fellow, or Junior faculty (instructor or assistant professor) with three (3) or less years (total from all institutions) on staff

• Qualified individual must be listed as both the primary author and presenting author on the abstract.

• Authors selected for oral presentations must be capable and comfortable presenting the abstract to a large audience and answering audience questions.

• Individuals who have previously won the SITC Presidential Award are ineligible for the same award.

Presidential Award

Established in 1991, the SITC Presidential Award serves as recognition to the young investigator deemed to have the most outstanding oral abstract presentation at the SITC Annual Meeting. This recipient is chosen from the four Presidential Travel Award recipients.

SITC Presidential Award recipient will receive:

$1,000 Honorarium

Up to $1,000 in Travel Reimbursement

1-Year Membership with SITC

Commemorative Presidential Award Plaque

Presidential Award Winner Poster Ribbon

Presidential Travel Awards

Four abstracts submitted in any category and authored by young investigators are selected for 20 minute oral presentations during the Presidential Session of the SITC Annual Meeting. Those presenting authors not selected for the SITC Presidential Award will receive a SITC Presidential Travel Award in recognition of their achievement. See past Presidential Travel Award recipients here.

SITC Presidential Travel Award recipients will receive:

Up to $750 in Travel Reimbursement

1-Year Membership with SITC

Presidential Travel Award Certificate

Presidential Travel Award Winner Poster Ribbon

Young Investigator Travel Awards

SITC offers Young Investigator Travel Awards to six young investigators who submitted an abstract for the SITC Annual Meeting. Judging of the abstracts is by a committee of SITC leadership and Annual Meeting organizers.

SITC Travel Award recipients will receive:

Up to $750 in Travel Reimbursement

SITC Travel Award Certificate

SITC Travel Award Winner Poster Ribbon

Questions?

For questions regarding award eligibility, submission deadlines, or other related abstract questions, please contact the SITC Office at 414-271-2456 or info@sitcancer.org.

Call for Applications: 2014 Association of Women Surgeons Foundation/Ethicon Endo-Surgery, Inc. Fellowship

A one year grant of $25,000 will be awarded to a qualified and approved grant applicant in the following research topic areas:

• Bariatrics

• Minimally Invasive Surgery

• Cancer Related Research

• Surgical Education

• Surgical Innovation

Applicant Qualifications

• Applicants must be a non-tenure or tenure-track faculty member in a Department of Surgery.

• Junior faculty applicants are encouraged to have a mentor for the submitted research proposal.

• Must be a current AWS member in good standing.

Individuals with research support such as national extramural grants are eligible, provided the projects do not have scientific overlap.  Applicants who do not have funding from other surgical societies will be given priority.  Officers and members of the AWS Grants and Fellowship Committee are excluded from mentoring applicants.

Grant Submissions are due July 1, 2013

For more information, contact AWSF at
5204 Fairmount Avenue - Downers Grove, IL  60515
Phone: 708-226-2725 - Fax: 630-493-0798

Email: INFO@WomenSurgeons.org  or visit our Website at WomenSurgeons.org.